Lexaria Bioscience Corp.
(C.LXX)

Lexaria is technology for improved delivery of bioactive compounds.

Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) is a research-driven company that has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes faster delivery of drugs into the bloodstream, healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

Lexaria’s DehydraTECH technology is covered by issued and pending patents in over 40 countries around the world. Lexaria’s first patent was issued by USPTO in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. Lexaria has filed for patent protection for delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors, tobacco and more.

Stock Quote

Company Name Lexaria Bioscience Corp.
Market/Symbol C.LXX
Industry Consumer Defensive, Packaged Foods
Market Cap $133.76 Million
Shares Outstanding 77.45 Million
Public Float
52 week Range 1.00 – 3.11
Average Volume 76,400
As of March 03, 2019

SIGN UP FOR Lexaria Bioscience EMAIL ALERTS

BE THE FIRST TO RECEIVE BREAKING NEWS

SIGN UP TODAY